Kyowa Kirin Co Ltd (KYKOF) Stock Price, Trades & News

Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	No Debt
Equity-to-Asset	0.84
Interest Coverage	19.05
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	5.24	Distress Grey Safe
Beneish M-Score	-2.43	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

6/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	8.6
	3-Year EBITDA Growth Rate	11.3
	3-Year EPS without NRI Growth Rate	8.7
	3-Year FCF Growth Rate	-34.8
	3-Year Book Growth Rate	6.3
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	10.04
	Future 3-5Y Total Revenue Growth Rate Estimate	3.12

Momentum Rank

4/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	99.99
	9-Day RSI	98.96
	14-Day RSI	92.27
	3-1 Month Momentum %	16.14
	6-1 Month Momentum %	-8.96
	12-1 Month Momentum %	-3.52

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.18
	Quick Ratio	2.73
	Cash Ratio	1.73
	Days Inventory	191.28
	Days Sales Outstanding	107.11
	Days Payable	307.96

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	2.81
	Dividend Payout Ratio	0.45
	3-Year Dividend Growth Rate	6.7
	Forward Dividend Yield %	3.09
	5-Year Yield-on-Cost %	4.02
	3-Year Average Share Buyback Ratio	0.9
	Shareholder Yield %	2.45

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	73.84
	Operating Margin %	21.54
	Net Margin %	14.28
	EBITDA Margin %	23.87
	FCF Margin %	1.41
	OCF Margin %	17.77
	ROE %	8.47
	ROA %	6.83
	ROIC %	12.03
	3-Year ROIIC %	5.89
	ROC (Joel Greenblatt) %	47.27
	ROCE %	10.98
	Years of Profitability over Past 10-Year	10
	Moat Score	6
	Tariff Resilience Score	5

GF Value Rank

8/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	17.98
	Forward PE Ratio	0.11
	PE Ratio without NRI	17.98
	Shiller PE Ratio	22.07
	Price-to-Owner-Earnings	245.01
	PEG Ratio	1.51
	PS Ratio	2.57
	PB Ratio	1.47
	Price-to-Tangible-Book	2.54
	Price-to-Free-Cash-Flow	242.59
	Price-to-Operating-Cash-Flow	14.74
	EV-to-EBIT	10.7
	EV-to-Forward-EBIT	13.2
	EV-to-EBITDA	8.7
	EV-to-Forward-EBITDA	10.23
	EV-to-Revenue	2.08
	EV-to-Forward-Revenue	2.27
	EV-to-FCF	196.35
	Price-to-GF-Value	0.8
	Price-to-Projected-FCF	1.24
	Price-to-Median-PS-Value	0.73
	Price-to-Peter-Lynch-Fair-Value	1.79
	Price-to-Graham-Number	1.43
	Price-to-Net-Current-Asset-Value	4.59
	Price-to-Net-Cash	17.17
	Earnings Yield (Greenblatt) %	9.35
	FCF Yield %	0.41
	Forward Rate of Return (Yacktman) %	12.88

GF Value™: $17.92

KYKOF

Warning Signs

Warning! GuruFocus detected 1 Medium warning sign with KYKOF. Try a 7-Day Free Trial to check it out.

Kyowa Kirin Co Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Kyowa Kirin Co Ltd Stock Events

Financials Calendars

Event	Date	Price ($)
JPY 35.000000 Cash Dividend	2026-06-29	In 3 days
JPY 32.000000 Cash Dividend	2025-12-29	15.85 (+0.00%)
JPY 30.000000 Cash Dividend	2025-06-27	14.95 (+0.00%)
JPY 29.000000 Cash Dividend	2024-12-27	15.32 (-7.46%)
JPY 29.000000 Cash Dividend	2024-06-27	17.00 (+0.00%)

Show

Entries

Guru Commentaries on OTCPK:KYKOF

No articles.

Press Release

	Subject	Date
	Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress	2025-07-29
	35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRIN	2025-04-03
	Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025	2025-02-26
	Kyowa Kirin Announces Positive Interim Real-world Data for Mogamulizumab (Poteligeo®) in Cutaneous T-cell Lymphoma at EORTC-CLTG 2024	2024-10-08
	Kyowa Kirin Presents Real-World Evidence Demonstrating Clinically Meaningful Impact of Burosumab Treatment in Adults with X-linked Hypophosphatemia	2024-10-01
	Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis	2024-09-25
	Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting	2024-09-19
	New Analysis Demonstrates Impaired Work Productivity and Increased Unemployment Rates in Adults with X-linked Hypophosphatemia (XLH)	2024-09-10
	Kyowa Kirin to end distribution of Fareston (toremefine) in the United States	2024-08-23
	Kyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC	2024-06-10

10/Page

Articles on Kyowa Kirin Co Ltd

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.